Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza
NCT ID: NCT05093998
Last Updated: 2021-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
700 participants
INTERVENTIONAL
2022-01-15
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Only patients with mild to moderate influenza, without complications, will be included in the study. Taking into account the seasonality of the pathology and the low percentage of influenza in the general structure of ARVI incidence, for the successful inclusion of all patients in the study during two epidemiological seasons. The study will enroll 700 patients aged 18 to 65 years with a confirmed clinical diagnosis of influenza to treatment (AV5080) and placebo cohorts (1:1).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1.
AV5080 at a daily dose of 160 mg
AV5080
oral hard gelatin capsules
Group 2.
Placebo
Placebo
Hard gelatin capsules with a white body
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AV5080
oral hard gelatin capsules
Placebo
Hard gelatin capsules with a white body
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Men and women between the ages of 18 and 65 (inclusive).
3. Outpatients (including those admitted at home) and inpatients hospitalized for epidemiological reasons, diagnosed with influenza (ICD 10: J10 Influenza caused by an identified influenza virus) of mild to moderate severity.
4. Positive result of the rapid enzyme immunoassay test for influenza virus at screening.
5. Increase in body temperature in the armpit up to ≥ 38.0 оС at screening (or within 24 hours before screening according to the patient's words).
6. Presence of at least one of the following symptoms of moderate severity on screening:
headache, weakness/malaise, muscle pain/aches, fever/chills.
7. The duration of the disease is no more than 48 hours at the time of screening according to the patient.
8. Consent of patients to use adequate methods of contraception throughout the study.
Adequate methods of contraception include the use of:
* oral or transdermal contraceptives;
* a condom or diaphragm (barrier method) with spermicide or
* an intrauterine device.
Exclusion Criteria
2. Individual intolerance to the drug AV5080 or its components. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
3. Presence of complications of influenza, signs of bacterial infection or severe flu at the time of screening.
4. Infectious diseases transferred during the last week before screening
5. The need for hospital treatment for influenza, with the exception of hospitalization for epidemiological indications.
6. Reception of neuraminidase inhibitors (zanamivir and oseltamivir), immunotropic drugs, systemic glucocorticosteroids, antibacterial drugs of systemic action within 1 month before screening. Taking drugs that prolong the QT interval on an ECG (quinidine, amiodarone, procainamide, phenothiazine derivatives) for 5 half-lives or less before screening.
7. A history of influenza vaccination within 3 months prior to screening.
8. Chronic diseases of the respiratory system (bronchial asthma, COPD,) in history.
9. Persons with metabolic disorders (diabetes mellitus, obesity of 2-3 degrees).
10. Hypokalemia at screening (potassium level less than 3.5 mmol/L)
11. Persons with chronic kidney disease, chronic liver disease, with certain neurological conditions (including neuromuscular, neurocognitive disorders, epilepsy), hemoglobinopathies or suppressed immune conditions, or due to primary immunosuppressive conditions such as HIV infection, or in connection with secondary immunodeficiency states due to the intake of immunosuppressive medications or malignant neoplasms.
12. Significant cardiovascular diseases at present or during 12 months before screening, including: prolongation of the QT interval on ECG more than 450 ms, atrioventricular block, sinus bradycardia, chronic cerebrovascular insufficiency, chronic heart failure class III or IV (according to the classification of the New York Heart Association), severe arrhythmia, requiring treatment with class Ia, Ib, Ic, or III antiarrhythmic drugs, unstable angina pectoris, myocardial infarction, heart and coronary artery surgery, significant heart valve disease, transient ischemic attack or stroke, uncontrolled hypertension with systolic blood pressure\> 180 mm Hg ... and diastolic blood pressure\> 110 mm Hg, pulmonary embolism or deep vein thrombosis.
13. A history of chronic alcoholism, drug addiction or dependence on other chemical compounds.
14. Participation in other clinical trials within 3 months prior to screening.
15. Inability to read or write; unwillingness to understand and follow research protocol procedures; non-compliance with the regimen of taking medications or performing procedures that, in the opinion of the Investigator, may affect the results of the study or the safety of the patient and prevent the patient from further participation in the study any other comorbid medical or serious mental condition that renders a patient ineligible for participation in a clinical research study, limits the ability to obtain informed consent, or may affect a patient's ability to participate in a study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Viriom
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Specialized Clinical Infectious Diseases Hospital
Krasnodar, , Russia
Murmansk Regional Clinic named after P.A. Bayandin
Murmansk, , Russia
Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
Novosibirsk, , Russia
Center for the Prevention and Control of AIDS and Infectious Diseases
Saint Petersburg, , Russia
First Saint Petersburg State Medical University named after I.I. Academician Pavlov
Saint Petersburg, , Russia
Research Center Eco-safety
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FLU-AV5080-03
Identifier Type: -
Identifier Source: org_study_id